Mirati Therapeutics, Inc. Common Stock
MRTX
MRTX was delisted on the 22nd of January, 2024.
233 hedge funds and large institutions have $2.95B invested in Mirati Therapeutics, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 43 funds opening new positions, 99 increasing their positions, 72 reducing their positions, and 47 closing their positions.
153% more call options, than puts
Call options by funds: $86.2M | Put options by funds: $34.1M
38% more repeat investments, than reductions
Existing positions increased: 99 | Existing positions reduced: 72
9% less first-time investments, than exits
New positions opened: 43 | Existing positions closed: 47
4% less funds holding
Funds holding: 243 → 233 (-10)
33% less capital invested
Capital invested by funds: $4.39B → $2.95B (-$1.43B)
33% less funds holding in top 10
Funds holding in top 10: 15 → 10 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$114M |
| 2 |
AC
Armistice Capital
New York
|
+$103M |
| 3 |
State Street
Boston,
Massachusetts
|
+$63M |
| 4 |
Morgan Stanley
New York
|
+$45.5M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$42.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$99.1M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$94.1M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$70.9M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$59.8M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$53.9M |
MRTX Hedge Fund Activity: Q4 2022 in Review
233 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Mirati Therapeutics, Inc. Common Stock (MRTX) for Q4 2022, worth a combined $2.95B — down 33% from $4.39B a quarter earlier.
Sellers outnumbered buyers: 47 funds closed out of MRTX and 43 opened new positions — a net loss of 4 holders — while 72 trimmed existing stakes and 99 added.
The largest buyer was RTW Investments, adding an estimated $114M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $99.1M sold.
- 233 institutional investors held Mirati Therapeutics, Inc. Common Stock (MRTX) as of Q4 2022, down from 243 in Q3 2022.
- Funds reported $2.95B of Mirati Therapeutics, Inc. Common Stock stock for Q4 2022, down 33% quarter-over-quarter.
- 43 funds opened new Mirati Therapeutics, Inc. Common Stock positions in Q4 2022 and 47 closed out, a net change of -4 holders.
- The largest Mirati Therapeutics, Inc. Common Stock buyer in Q4 2022 was RTW Investments, an estimated $114M added.
- The largest Mirati Therapeutics, Inc. Common Stock seller in Q4 2022 was Adage Capital Partners, an estimated $99.1M sold.
Based on aggregated 13F filings for Q4 2022.